Status:
COMPLETED
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
Lead Sponsor:
Dow Pharmaceutical Sciences
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
Eligibility Criteria
Inclusion
- Presence of acne vulgaris on the face and neck/trunk
- Presence of inflammatory and non-inflammatory lesions on the face
Exclusion
- Presence of any skin condition on the face that could interfere with clinical evaluations
- Use of any systemic antibiotics or corticosteroids within 4 weeks prior to the Baseline visit
- Use of any systemic retinoids, such as isotretinoin, within 3 months prior to the Baseline visit
- Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT01194375
Start Date
September 1 2010
End Date
December 1 2011
Last Update
July 2 2012
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Specialists, Inc.
Oceanside, California, United States, 92056
2
Horizons Clinical Research Center, LLC
Denver, Colorado, United States, 80220
3
North Florida Dermatology Associates, PA
Jacksonville, Florida, United States, 32204
4
FXM Research Corp.
Miami, Florida, United States, 33175